Acid Suppression and Peptic Ulcer Disease
Parietal cell physiology · Proton pump inhibitors · H2 receptor antagonists · Helicobacter pylori eradication · Cytoprotective agents
Parietal Cell: Three Inputs, One Pump
Input 1
Histamine
From ECL cells → H2 receptor → Gs → cAMP → PKA
Input 2
Gastrin
From G cells → CCK-B receptor → Ca2+ and ECL histamine release
Input 3
Acetylcholine
Vagal → M3 receptor → Gq → Ca2+
Final effector
H+/K+ ATPase
Secretes H+ into lumen → pH ~1.0
Acid-Suppressive Drug Classes Compared
| Feature |
Proton Pump Inhibitors |
H2 Receptor Antagonists |
Notes |
| Target |
H+/K+ ATPase (pump) |
Histamine H2 receptor |
PPIs act downstream of all receptor inputs |
| Block type |
Irreversible covalent |
Competitive reversible |
PPIs suppress ~90%; H2RAs ~65% |
| Onset |
Delayed; days to full effect |
Rapid (1–2 hours) |
H2RAs better for on-demand relief |
| Timing rule |
30–60 min before first meal |
With or without food |
PPI timing is non-negotiable |
| Tolerance |
No |
Yes (1–2 weeks) |
H2RAs not suitable for long-term maintenance |
| Preferred agent |
Any; pantoprazole if on clopidogrel |
Famotidine (not cimetidine) |
Cimetidine: multiple CYP interactions |
Proton Pump Inhibitor: Key Pharmacology
Mechanism
Prodrug Activation
- Absorbed in small intestine
- Concentrated in acidic canaliculus
- Acid converts prodrug to sulfenamide
- Covalent bond to H+/K+ ATPase cysteine
- Irreversible: new pump synthesis required (~18 hrs)
CYP2C19 Pharmacogenomics
Metabolizer Status Matters
- Ultrarapid metabolizers: lower drug exposure, treatment failure risk
- Poor metabolizers: higher exposure, greater acid suppression
- Rabeprazole: least CYP2C19-dependent
- Pantoprazole: minimal CYP2C19 inhibition — use with clopidogrel
- Omeprazole/esomeprazole: inhibit CYP2C19 → reduce clopidogrel activation
Long-Term Adverse Effects
Monitor for These
- Hypomagnesemia: oral Mg does not fix; stop PPI
- Clostridioides difficile risk increased
- Calcium malabsorption: use calcium citrate
- Rebound hypersecretion on abrupt stop: taper
- B12 malabsorption with very long-term use
Helicobacter pylori Eradication
First-Line Regimens (14 days)
Choose Based on Local Resistance
- Triple therapy (clarithromycin resistance <15%): PPI + amoxicillin + clarithromycin
- Bismuth quadruple (resistance >15% or prior macrolide): PPI + bismuth + metronidazole + tetracycline
- Both for 14 days (not 7 days)
- PPI dose twice daily; higher dose if CYP2C19 ultrarapid metabolizer
Diagnostic Testing
Urea Breath Test or Stool Antigen Test
- Urea breath test: labeled urea → urease → labeled CO2 in breath; >95% sensitivity and specificity
- Stool antigen test: equivalent accuracy
- Stop PPI 2 weeks before testing
- Stop antibiotics/bismuth 4 weeks before testing
- Serology: cannot confirm eradication — do not use for post-treatment testing
Cytoprotective Agents
Antacids
Neutralize Acid Transiently
- Al(OH)3: constipating; Mg(OH)2: laxative; combine to balance
- Duration: 1–2 hours only
- Chelate fluoroquinolones, tetracyclines, iron, bisphosphonates — separate by 2+ hours
- Role: on-demand mild heartburn only
Sucralfate
Physical Barrier at Ulcer
- Polymerizes at low pH → adheres to ulcer crater
- Barrier lasts up to 6 hours per dose
- Does not neutralize acid
- Avoid in severe renal impairment (aluminum)
- Separate from fluoroquinolones, warfarin, phenytoin, digoxin, thyroid hormone by 2 hours
- Used for stress ulcer prophylaxis in ICU
Misoprostol
PGE1 Analog — Contraindicated in Pregnancy
- Prostaglandin E1 analog: replaces COX-1-derived prostaglandins
- Stimulates mucus, bicarbonate, mucosal blood flow
- Used for NSAID gastroprotection (40% ulcer reduction)
- Adverse effects: diarrhea, cramping (dose-dependent)
- ABSOLUTE CI IN PREGNANCY: causes uterine contractions, miscarriage, preterm labor
Critical Rule — Misoprostol
Misoprostol is FDA Pregnancy Category X. Confirm absence of pregnancy and ensure reliable contraception before prescribing for any indication. In women of childbearing potential requiring NSAID gastroprotection, use a proton pump inhibitor instead.